American Heart Association awards $2.1m to research link between migraine, strokes and CVD
July 27, 2023Research and Development American Heart Association, Cardiology, cvd, migraine, stroke
The American Heart Association has announced that it will fund seven new scientific research studies to learn more about the …
Amarin gains positive opinion from Spanish Drug Pricing Committee for national reimbursement of Vazkepa in Spain
July 26, 2023Sales and Marketing Amarin, Cardiology, Spanish Drug Pricing Committee, Vazkepa, cardiovascular
Amarin has announced that the Spanish Drug Pricing Committee has recommended the national reimbursement of Vazkepa (icosapent ethyl) in Spain …
Biovian announces investment in manufacturing facility in Finland
July 26, 2023Manufacturing and Production Biovian, Pharmacy, facility, manufacturing
Biopharmaceutical based contract development and manufacturing organisation (CDMO) Biovian OY has announced an investment of over €50m to expand its …
AbbVie announces first patient dosed in phase 3 trial of upadacitinib in hidradenitis suppurativa
July 25, 2023Research and Development AbbVie, Dermatology, HS, Rinvoq, clinical trial, upadacitinib
AbbVie has announced that the first patient has been dosed in its phase 3 Step-Up trial assessing Rinvoq (upadacitinib) for …
Bavarian Nordic announces RSV vaccine did not meet all primary endpoints in phase 3 trial
July 25, 2023Medical Communications Bavarian Nordic, Infections and infestations, RSV, Vaccine, clinical trial
Bavarian Nordic has announced that its phase 3 clinical trial of MVA-BN, its respiratory syncytial virus (RSV) vaccine candidate for …
ViiV Healthcare gains positive CHMP opinion for cabotegravir for HIV prevention
July 24, 2023Medical Communications CHMP, EMA, HIV, HIV/AIDS, ViiV Healthcare, cabotegravir
GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal …
Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension
July 24, 2023Research and Development Alnylam, Cardiology, Roche, hypertension, rnai, zilebesiran
Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, …
Aevice Health gains FDA clearance for respiratory monitoring platform
July 21, 2023Research and Development Aevice Health, Devices, FDA, respiratory monitoring
Remote respiratory monitoring solutions company Aevice Health has announced that it has received clearance from the US Food and Drug …
BioIVT acquires PrecisionMed for neurology and oncology research
July 21, 2023Sales and Marketing Neurology, Oncology, neurology, oncology
BioIVT has announced that it has acquired PrecisionMed, a leading supplier of high-quality human biological material for genetics, drug discovery …
WHO releases Medical Product Alert for contaminated cough syrup
July 20, 2023Medical Communications Pharmacy, WHO, cough syrups, medical product alert, world health organization
The World Health Organization (WHO) has shared a Medical Product Alert for an additional contaminated cough syrup medicine identified in …
Pfizer shares new data from phase 2 trial for GBS maternal vaccine candidate
July 20, 2023Research and Development Immunology, Pfizer, Vaccine, clinical trial
Pfizer has announced new data from its phase 2 study which assessed its hexavalent capsular polysaccharide (CPS) conjugate Group B …
Santhera closes exclusive license agreement with Catalyst Pharmaceuticals for Vamorolone
July 19, 2023Medical Communications License Agreement, Musculo-skeletal disorder, Vamorolone, catalyst, santhera
Santhera Pharmaceuticals has announced the closing of its exclusive North American license agreement for vamorolone with Catalyst Pharmaceuticals. The agreement …
Renibus Therapeutics announces $47m financing for phase 3 trial
July 19, 2023Business Services Cardiology, Financing, Renibus Therapeutics, clinical trial
Clinical stage biopharmaceutical company Renibus Therapeutics has announced that it has raised $47m from the initial closing of its Series …
Eli Lilly shares results from phase 3 trial of donanemab for Alzheimer’s treatment
July 18, 2023Research and Development Alzheimer's, Eli Lilly, Neurology, clinical trial, donanemab
Eli Lilly has presented full results from the phase 3 TRAILBLAZER-ALZ 2 study which assessed donanemab for the treatment of …
FDA approves AstraZeneca’s drug to prevent RSV in babies and young children
July 18, 2023Research and Development AstraZeneca, FDA, Immunology, RSV, Vaccine, paediatrics
The US Food and Drug Administration (FDA) has announced that it has approved Beyfortus (nirsevimab-alip) for the prevention of respiratory …
Inizio Engage launches Patient Access Services – an integrated suite of patient support services to enhance access and adherence for specialty therapies
July 18, 2023Business Services Inizio Engage, Patient Access Services, Pharmacy, patient support
Fort Washington, US — Inizio Engage is pleased to announce the launch of Patient Access Services. This custom-built, integrated suite of patient support services …
Alnylam shares positive results from phase 1 trial
July 17, 2023Research and Development ALN-APP, Alnylam, Alzheimer's disease, Cerebral Amyloid Angiopathy, Neurology, clinical trial
Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of its phase 1 study of …
Eli Lilly to acquire Versanis Bio for $1.9bn
July 17, 2023Sales and Marketing Cardiology, Eli Lilly, Versanis Bio, acquisition, cardiometabolic diseases
Eli Lilly and Versanis Bio have announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company …
FDA approves first OTC daily oral contraceptive pill
July 14, 2023Medical Communications Contraception, FDA, OTC, Opill, contraceptive pill
The US Food and Drug Administration (FDA) has announced that it has approved the Opill (norgestrel) tablet for nonprescription use …
EMA accepts Astellas’ MAA for Zolbetuximab
July 14, 2023Medical Communications Astellas, Cancer, EMA, Oncology, zolbetuximab
Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the company’s marketing authorisation application (MAA) for regulatory …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
